"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 |
| 1996 | 2 | 3 | 5 |
| 1997 | 3 | 5 | 8 |
| 1998 | 10 | 5 | 15 |
| 1999 | 1 | 1 | 2 |
| 2000 | 5 | 3 | 8 |
| 2001 | 8 | 3 | 11 |
| 2002 | 12 | 6 | 18 |
| 2003 | 3 | 10 | 13 |
| 2004 | 9 | 9 | 18 |
| 2005 | 11 | 8 | 19 |
| 2006 | 6 | 14 | 20 |
| 2007 | 10 | 11 | 21 |
| 2008 | 9 | 23 | 32 |
| 2009 | 9 | 9 | 18 |
| 2010 | 13 | 8 | 21 |
| 2011 | 2 | 2 | 4 |
| 2012 | 8 | 8 | 16 |
| 2013 | 9 | 9 | 18 |
| 2014 | 16 | 9 | 25 |
| 2015 | 14 | 13 | 27 |
| 2016 | 14 | 6 | 20 |
| 2017 | 19 | 11 | 30 |
| 2018 | 9 | 12 | 21 |
| 2019 | 7 | 10 | 17 |
| 2020 | 15 | 10 | 25 |
| 2021 | 11 | 11 | 22 |
| 2022 | 2 | 10 | 12 |
| 2023 | 1 | 10 | 11 |
| 2024 | 5 | 8 | 13 |
| 2025 | 3 | 4 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Disease Outcomes in Immune-Mediated Colitis: A Study Describing Initial Endoscopic and Histologic Presentations and Treatment Options. J Natl Compr Canc Netw. 2025 Sep; 23(9).
-
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial. Blood Adv. 2025 Aug 12; 9(15):3728-3738.
-
Successful Treatment of Double-Positive Rapidly Progressive Glomerulonephritis: A Case Report. J Investig Med High Impact Case Rep. 2025 Jan-Dec; 13:23247096251365418.
-
Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy. Transplant Cell Ther. 2025 Oct; 31(10):826.e1-826.e10.
-
The effect of CTLA4-Ig on fibrotic progression in a murine model of chronic lung allograft dysfunction. J Heart Lung Transplant. 2025 Sep; 44(9):1504-1509.
-
Sirolimus utilization in pediatric liver transplantation: A large high-volume quaternary center experience. J Pediatr Gastroenterol Nutr. 2025 Aug; 81(2):167-176.
-
Association Between Early Immunosuppression Center Variability and One-Year Outcomes After Pediatric Liver Transplant. Pediatr Transplant. 2025 Feb; 29(1):e70018.
-
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial. Arthritis Rheumatol. 2025 May; 77(5):571-581.
-
Budesonide, Added to PTCy-Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation. Am J Hematol. 2025 Mar; 100(3):383-392.
-
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703. J Clin Oncol. 2025 Mar 10; 43(8):912-918.